With leading injectables at 20% to 28% weight loss, GLP-1 competition is shifting to oral convenience, tolerability, persistence, lean mass, and comorbidity labels. This is the interactive data behind our GLP-1 and Metabolic Intelligence Report, Q3 2026, as of August 2026. Click any chart, card, or row to see what sits behind it.
